首页> 外文期刊>European Journal of Pharmacology: An International Journal >I kappa B kinase beta inhibitor, IMD-0354, prevents allergic asthma in a mouse model through inhibition of CD4(+) effector T cell responses in the lung-draining mediastinal lymph nodes
【24h】

I kappa B kinase beta inhibitor, IMD-0354, prevents allergic asthma in a mouse model through inhibition of CD4(+) effector T cell responses in the lung-draining mediastinal lymph nodes

机译:I kappa B激酶beta抑制剂IMD-0354通过抑制肺引流性纵隔淋巴结中的CD4(+)效应子T细胞反应,预防小鼠模型中的过敏性哮喘

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

I kappa B kinase (MK) is important for nuclear factor (NF)-kappa B activation under inflammatory conditions. It has been demonstrated that IMD-0354, i.e. a selective inhibitor of IKK beta, inhibited allergic inflammation in a mouse model of ovalbumin (OVA)-induced asthma. The present study attempts to shed light on the involvement of CD4(+) effector (Teff) and regulatory (Treg) T cells in the anti-asthmatic action of IMD-0354. The animals were divided into three groups: vehicle treated, PBS-sensitized/challenged mice (PBS group); vehicle treated, OVA-sensitized/challenged mice (OVA group); and [MD-0354-treated, OVA-sensitized/challenged mice. The analyzed parameters included the absolute counts of Treg cells (Foxp-3'CD25-'CD4-1, activated Teff cells (Foxp3-CD25-'CD4-1 and resting T cells (CD25-CD4-') in the mediastinal lymph nodes (MLNs), lungs and peripheral blood. Moreover, lung histopathology was performed to evaluate lung inflammation. It was found that the absolute number of cells in all studied subsets was considerably increased in the MLNs and lungs of mice from OVA group as compared to PBS group. All of these effects were fully prevented by treatment with IMD-0354. Histopathological examination showed that treatment with IMD-0354 protected the lungs from OVA -induced allergic airway inflammation. Our results indicate that IMD-0354 exerts anti-asthmatic action, at least partially, by blocking the activation and clonal expansion of CD4(+) Teff cells in the MLNs, which, consequently, prevents infiltration of the lungs with activated CD4(+) Teff cells. The beneficial effects of IMD-0354 in a mouse model of asthma are not mediated through increased recruitment of Treg cells into the MLNs and lungs and/or local generation of inducible Treg cells. (C) 2016 Elsevier B.V. All rights reserved.
机译:IκB激酶(MK)对于炎症条件下的核因子(NF)-κB活化很重要。已经证明IMD-0354,即IKKβ的选择性抑制剂,在卵白蛋白(OVA)诱导的哮喘小鼠模型中抑制了过敏性炎症。本研究试图阐明IMD-0354的抗哮喘作用中CD4(+)效应子(Teff)和调节性(Treg)T细胞的参与。将动物分为三组:媒介物处理的,PBS致敏/挑战的小鼠(PBS组);和媒介物治疗的OVA致敏/激发小鼠(OVA组);和[MD-0354处理的,OVA致敏/攻击的小鼠。分析的参数包括纵隔淋巴结中Treg细胞(Foxp-3'CD25-'CD4-1',活化的Teff细胞(Foxp3-CD25-'CD4-1)和静息T细胞(CD25-CD4-')的绝对计数(MLN),肺和外周血,并进行了肺组织病理学评估以评估肺部炎症,发现与PBS相比,OVA组小鼠的MLN和肺中所有研究亚群中的绝对细胞数量均显着增加IMD-0354治疗可完全预防所有这些作用,组织病理学检查显示,IMD-0354治疗可保护肺部免受OVA诱发的过敏性气道炎症反应,我们的结果表明IMD-0354在IMD-0354在小鼠模型中的有益作用是通过阻止MLN中CD4(+)Teff细胞的活化和克隆扩增,从而防止肺部被活化的CD4(+)Teff细胞浸润。没有哮喘通过增加Treg细胞向MLN和肺中的募集和/或诱导型Treg细胞的局部产生来介导t t介导。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号